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Abstract
Background
Country decisions to scale-up “test and treat” approaches for HIV depend on consideration
of both the health and economic consequences of such investments. Evidence about eco-
nomic impacts of expanded antiretroviral therapy (ART) provision is particularly relevant for
decisions regarding foreign assistance levels for HIV/AIDS programs. We used baseline
data from the Sustainable East Africa Research in Community Health (SEARCH) cluster
randomized controlled trial in Kenya and Uganda to examine the association between HIV
status, CD4+ T-cell counts, viral suppression, and multiple indicators of economic well-
being.
Methods and findings
Socio-economic surveys were conducted in households with HIV-positive and HIV-negative
adults sampled after a census of 32 communities participating in the SEARCH trial
(NCT01864603). Data were obtained for 11,500 individuals from 5,884 households in study
communities. Participants were stratified based on their own HIV status as well as CD4
counts and viral suppression status if they were HIV-positive. HIV-negative participants
residing in households with no HIV-positive adults were considered separately from HIV-
negative participants residing in households with1 HIV-positive adult. Generalized esti-
mating equation models were used to examine the relationship between HIV status, CD4
counts, ART, viral suppression, and outcomes of employment, self-reported illness, lost
time from usual activities due to illness, healthcare utilization, health expenditures, and
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There was no significant difference in the probability of being employed between HIV-
positive participants with CD4>500 and the reference group of HIV-negative participants
residing in households with no HIV-positive adults (marginal effect, ME, 1.49 percentage
points; 95% confidence interval, CI, -1.09, 4.08). However, HIV-positive participants with
CD4 351–500 were less likely to be employed than the reference group (ME -4.50, 95% CI
-7.99, -1.01), as were HIV-positive participants with CD4350 (ME -7.41, 95% CI -10.96,
-3.85). Similarly, there was no significant difference in employment likelihood between HIV-
negative participants who resided in households with a CD4>500 HIV-positive person and
the reference group (ME -1.78, 95% CI -5.16, 1.59). HIV-negative participants residing with
an HIV-positive person with CD4 351–500, however, were less likely to be employed than
the reference group (ME -7.03, 95% CI -11.49, -2.57), as were people residing with a house-
hold member with CD4350 (ME -6.28, 95% CI -10.76, -1.80). HIV-positive participants in
all CD4 categories were more likely to have lost time from usual activities due to illness and
have incurred healthcare expenditures. Those with CD4>500 had better economic out-
comes than those with CD4 351–500, even among those not virally suppressed (p = 0.004)
and not on ART (p = 0.01).
Conclusions
Data from a large population-representative sample of households in east Africa showed a
strong association between the health of HIV-positive persons and economic outcomes.
The findings suggest there may be economic benefits associated with maintaining high CD4
counts, both for HIV-positive persons and their HIV-negative household members. The
association of high CD4 counts with improved outcomes is consistent with the hypothesis
that early ART initiation can avert declines in employment and other economic outcomes.
Prospective longitudinal evaluation is needed to assess the causal impact of early ART initi-
ation on economic functioning of households.
Introduction
Compelling evidence on the public health benefits of antiretroviral (ART) treatment as preven-
tion and the individual-level benefits of early ART initiation [1, 2] was the foundation for the
2015 WHO guidelines that recommend treatment for all persons living with HIV. Given the
promise ART now holds for HIV-positive people and the broader population, the UNAIDS
established the ‘90-90-90 targets’ that call for 90% coverage of HIV testing, ART initiation, and
treatment adherence among HIV-positive persons [3, 4]. Despite these data and recommenda-
tions, less than half of countries have adopted the WHO guidelines and pace of adaptation is
threatened even among countries moving forward to “HIV test and treat” [5]. Despite the
strong public health case and economic rationale, a number of factors including resource con-
straints have contributed to these delays [3, 6–8]. Uncertainty about levels of support from the
US government for HIV/AIDS programs through the President’s Emergency Plan For AIDS
Relief (PEPFAR) and other initiatives [9] could put an even greater financial burden on low-
income countries that depend on this financing. Policymakers could therefore benefit from
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assessments of the potential economic gains of finding and keeping HIV-positive persons in
the high CD4 range through early ART initiation—gains that may be realized by the affected
HIV-positive individual and their household members.
Longitudinal studies conducted in sub-Saharan Africa (SSA) during the past decade show
that ART initiation among individuals with low CD4+ T-cell counts, in line with prior WHO
guidelines, leads to dramatically improved individual- and household-level economic out-
comes [10–18]. These studies report sustained improvements in outcomes ranging from labor
force participation, income, and quality of life for the individuals receiving ART. A limited
number of additional studies have also documented benefits to household members of treated
adults, particularly in the form of reduced domestic labor burden [19] and increased school
enrollment for children [20]. One study also showed that ART expansion led to increased
work hours of HIV-negative people whose households did not directly benefit from the treat-
ment [21]. Although these studies offer persuasive evidence of the economic recovery follow-
ing ART initiation for those with low CD4 counts, no study to date assessed whether ART
initiation among asymptomatic patients with CD4 counts above 500 cells/μl also generates
economic benefits. Crucial to the discussion of economic benefits of “test and treat” is the
hypothesis that delayed ART initiation may lead to a period of health and economic decline
along with incomplete recovery even when patients adhere to ART. Thus, averting a decline of
outcomes through early ART initiation may offer important benefits that extend beyond the
health sector.
Although a positive association between employment outcomes and CD4 counts among
those not on ART has previously been documented in a rural Ugandan setting [22] and a
study from South Africa has shown that employment outcomes decline in the years prior to
ART initiation [15], data from a larger population on a wider set of indicators of economic
well-being are lacking. Furthermore, information on viral loads of HIV-positive persons has
seldom been integrated into analyses. Because most studies have focused on outcomes of
patients initiating ART, less is also known about how HIV-negative household members fare
when an HIV-positive household member has high vs. low CD4 counts. This study utilizes
detailed socio-economic and laboratory data collected as part of a community cluster random-
ized trial conducted in east Africa to examine the association between HIV status, CD4 counts,
viral suppression and ART initiation, and multiple indications of economic well-being.
Methods
Study procedures
Data were collected in 32 rural communities participating in the ongoing Sustainable East
Africa Research in Community Health (SEARCH) HIV “test and treat” cluster randomized
controlled trial (NCT01864603). The trial procedures have been described in detail elsewhere
[23]. Briefly, study communities consisting of approximately 10,000 individuals each are
located in three distinct geographic regions with varying HIV prevalence; 12 communities are
in western Kenya, 10 in eastern Uganda, and 10 in southwestern Uganda. At the beginning of
the trial (baseline), a door-to-door census was conducted in each community and was followed
by 2-week multi-disease community health campaigns (CHCs) that included HIV testing,
counselling, and referral to care for HIV-positive persons. Individuals aged>10 years who
participated in census but did not attend the CHCs were subsequently approached for home-
based testing. This “hybrid” testing approach was found to achieve 89% population-level HIV
testing coverage [23].
Following the CHCs and home-based testing, a random sample of households with and
without an HIV-positive adult were selected for structured household socio-economic (HSE)
High CD4 counts associated with better economic outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0198912 June 26, 2018 3 / 18
surveys. The CHC campaigns usually took place 2 weeks prior to the start of HSE data collec-
tion. Sampling of household occurred after the door-to-door census and the ‘hybrid’ testing
approach was completed in each community. These activities made it possible to assess HIV
status of nearly all community members, which was then used for sampling purposes. For the
HSE surveys, households with HIV-positive adults were over-sampled in each community
given the likelihood that these households would be most directly affected by the primary
intervention in the SEARCH trial (i.e. earlier initiation of HIV treatment). All households
were classified as having at least one HIV-positive adult (18 years) or having no HIV-positive
adults. In each community, we sampled 100 households that included an HIV-positive adult
and 100 households that did not include an HIV-positive adult.
The HSE surveys, adapted from the World Bank’s Living Standards Measurement Surveys
[24], sought to assess socio-economic conditions of households and individuals residing in
them. They consisted of individuals’ demographic characteristics, employment and income of
household members aged12 years, ownership of durable goods and livestock, healthcare uti-
lization, and education of household members aged 6–25 years. Reports about all household
members were obtained from one adult, typically the household head or spouse of household
head. Survey questionnaires were administered by trained research assistants who visited the
households. Information collected in the household surveys was linked at the individual level
to SEARCH data on HIV status, and for HIV-positive individuals, on CD4 count and viral
load.
Ethics statement
The Makerere University School of Medicine Research and Ethics Committee (Uganda), the
Uganda National Council for Science and Technology (Uganda), the Kenya Medical Research
Institute Scientific Ethics Review Unit (Kenya), and the University of California San Francisco
Committee on Human Research (USA) approved the consent procedures and the study. All
participants provided verbal informed consent in their preferred language with a signature or
fingerprint confirmation of consent.
Outcome measures
Participation in the labor force was assessed with a binary indicator of whether an individual
spent any time working (both on- or off-farm) in the week prior to the survey. Since most
households were primarily engaged in subsistence farming, we separately evaluated participa-
tion in the agriculture sector with a binary indicator of whether an individual did any farm
work in the past week. Self-reported health of study participants was measured with an indica-
tor of any illness episodes in the past month. An illness episode included any type of illness or
injury, for example cough, cold, diarrhea, or injury due to an accident. The potential economic
burden of illness was measured with an indicator of whether the participant lost time from
usual activities (employment and domestic activities) due to illness in the past month. Health-
care utilization was measured as a binary indicator of any care sought or received last month,
any health expenditures last month, and any hospitalizations in the past year. Healthcare
expenditures included travel for medical care costs, inpatient and outpatient fees, medicines,
laboratories, and other healthcare costs. The recall period for hospitalization was one year
prior to interview given the rarity of such events.
Laboratory-confirmed indicators
HIV status of individuals was determined by rapid HIV tests obtained in the hybrid testing
approach, i.e. CHCs and home-based testing. Laboratory-confirmed CD4+ T-cell/μL counts
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measured at baseline CHCs and home-based testing were used to characterize HIV-positive
participants’ disease stages [23]. HIV RNA levels were measured as previously described [25];
viral suppression was defined by RNA levels <500 copies/μL. Finally, we used ART start date,
based on information extracted from Ministry of Health data and study records, to determine
whether HIV-positive participants initiated ART at least 1 month prior to the household
survey.
Statistical analyses
We conducted two sets of complementary analyses. First, we focused on HIV-positive persons
and examined the association between HIV status, HIV disease progression, and socio-eco-
nomic outcomes. We compared outcomes of HIV-positive participants grouped by their CD4
counts to outcomes of HIV-negative participants in households without an HIV-positive per-
son (a group of individuals that would be least-affected by HIV/AIDS). HIV-positive partici-
pants were grouped by their CD4 counts in three categories that reflect various thresholds
used for ART initiation: >500 cells/μL, 351–500 cells/μL, and350 cells/μL.
Second, we focused on HIV-negative persons and sought to examine the association
between having an HIV-positive household member and various socio-economic outcomes.
We therefore compared outcomes of HIV-negative participants grouped by their HIV-positive
household members’ CD4 counts to the outcomes of HIV-negative participants in households
without any HIV-positive person. HIV-negative participants in households with an HIV-posi-
tive person were grouped based on the HIV-positive person’s CD4 count. In cases where a
household had2 HIV-positive persons, the lowest CD4 count was used to categorize partici-
pants. In all models, HIV-negative participants who lived in households without any HIV-pos-
itive person served as the reference group.
We estimated the following regression models:
Yijk ¼ HIV CD4
0
ijk mþ ARTijk bþ X
0
ijt φþ gk þ εijk ð1Þ
where i indexed individual living in household j in community k. HIV_CD4was a vector of
HIV status and CD4 count categories, ART indicated whether the individual had initiated
ART at least one month prior to the interview, and X was a vector of individual- and house-
hold-level characteristics: age, age-squared (to capture non-linear effects of age), education
(indicators for no education, some primary education, completed primary education, some
secondary education, and completed secondary education or greater), gender (indicator for
female), marital status (indicator for married or cohabiting), wealth index (in quintiles), num-
ber of children in household, and household size. ART status was included as a control variable
in order to allow for the possibility that individuals with similar CD4 counts might have differ-
ent outcomes depending on whether they were on ART. In order to retain HIV-negative par-
ticipants in the model as the reference group, they were coded as “not on ART”. Community
fixed effects, γk, were included to control for underlying differences between the study com-
munities. Wealth index was calculated using the first component of a principal component
analysis of ownership indicators of 47 different household items [26].
We used generalized estimating equations (GEE) regression models to analyze binary
dependent variables as a function of HIV status and HIV disease stages, defined by laboratory-
confirmed CD4 T-cell counts. We fitted GEE models using binomial distribution, logistic link,
and exchangeable correlation at the household level [27]. Given the difficulty of interpreting
logistic regression coefficients (log odds) and exponentiated coefficients (odds ratios), we
instead report average marginal effects (ME). Marginal effects represent the percentage point
change in predicted probability of the outcome for a one unit increase of the independent
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variable (or percentage point change from base for discrete variables), holding all other vari-
ables constant. We restricted the analytic sample to individuals who had non-missing data for
all outcomes and explanatory variables of interest. Post estimation Wald tests were used to per-
form two-sided hypothesis tests about equality of the CD4>500 coefficient to the CD4 351–
500 and CD4350 coefficients (and the equivalent of HIV-negative participant groups based
on HIV-positive household members’ CD4 counts).
We also tested whether there was an association between CD4 counts and economic out-
comes among HIV-positive participants based on their ART and viral suppression status. This
GEE estimation sub-categorized HIV-positive participants in the 3 CD4 groups by whether
they initiated ART and whether they reached viral suppression. High CD4 participants who
were virally suppressed were assumed to have achieved recovery in health status through ART.
High CD4 participants who were not virally suppressed were assumed to include newly
infected HIV participants identified through the comprehensive SEARCH testing strategy, as
described above, and patients who have been on ART but have not reached viral suppression.
We also performed Wald tests to determine whether the association for those with CD4>500
not on ART was the same as for those with CD4>500 on ART and CD4 351–500 CD4 not on
ART. Similar tests were performed with the viral suppression indicators.
Finally, we used nonparametric kernel-weighted local polynomial regression (with Epa-
nechnikov kernels and zero degree polynomials for local mean smoothing) to visually examine
the association between CD4 counts and study outcomes.
Results
Study participants
Data for 34,029 individuals living in 6,309 households were collected between July 2013 and
August 2014. This sample represented 10.2% of the 335,024 residents in the SEARCH trial
communities at baseline. We limited our analytic sample to working-age adults, defined as
those aged 18–65 years (n = 14,449) whose HIV status was known (n = 11,873) and whose
CD4 laboratory results were available if HIV-positive (n = 11,705). Participants with missing
HIV test results were primarily male (63%), unmarried (53%), and young (50% aged<25
years and 75% aged<35 years). The final analytic sample was further restricted to participants
who had non-missing data on outcomes and explanatory variables (n = 11,500 from 5,884
households).
Table 1 summarizes outcomes and other descriptive characteristics of the working-age
adults in our sample with non-missing data. By design, nearly half the sample (48%) consisted
of HIV-negative participants in households with no HIV-positive persons. Twenty-one per-
cent of participants were HIV-negative and lived in households with1 HIV-positive person.
Approximately 31% of all participants (n = 3,626) were HIV-positive, and 50% (n = 1,798) of
those individuals had CD4>500, 24% (n = 887) had CD4 351–500, and 26% (n = 941) had
CD4350.
More than half of participants (56%) had completed less than primary education, with
HIV-negative individuals having higher education and slightly higher household wealth. The
average age among participants was 35 years and nearly 58% were women. Majority of partici-
pants were active in the labor force in the past week, with 70% and 58% of all participants
reporting having done any work and farm work, respectively. Labor force participation rates
were lowest for HIV-negative participants in households with1 HIV-positive person.
Approximately one-third of all participants reported an illness in the past month and nearly
one-fifth of all participants reported having sought or received healthcare in the past month,
having lost time from usual activities due to illness, and having spent money on treatment in
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the past month. Hospitalization in the previous year was reported by 7% of all participants,
with HIV-positive participants being most likely to be hospitalized. Overall, HIV-positive par-
ticipants reported more illness and higher healthcare expenditures.
Regression results
Fig 1 displays the results of nonparametric regressions that estimated the unadjusted association
between CD4 counts and four indicators of employment and healthcare utilization outcomes
among HIV-positive adults. HIV-positive adults with higher CD4 counts had higher probability
of work last week, lower probability of losing time from usual activities due to illness, lower proba-
bility of spending time seeking healthcare or losing time from usual activities due to illness. Gen-
erally, the largest changes in probability of outcomes were associated with the lowest CD4 counts,
below 350 cells, at which point the probability continued to change but at a lower rate.
Employment outcomes of HIV-positive adults. Results in Table 2 show the association
of health status of HIV-positive participants, as indicated by CD4 counts, with employment
Table 1. Descriptive characteristics of study participants.
Study Group
HIV-,
no HIV+ household
members
HIV-,
lives with HIV+ household
members
HIV+
CD4
>500
HIV+
CD4 351–
500
HIV+
CD4
350
Full
Sample
No. individuals in study group 5,556 2,318 1,798 887 941 11,500
Percent of full sample in study group 48.3 20.2 15.6 7.7 8.2 100
Study outcomes
Worked last week, % 70.9 58.8 79.2 75.8 74.3 70.4
Worked on a farm last week, % 58.7 49.2 63.1 62.3 57.4 57.7
Experienced illness last month, % 28.2 22.1 37.3 42.6 43.6 30.8
Lost time from usual employment or household activities
due to illness last month, %
17.1 12.8 24.1 27.2 28.7 19.1
Sought or received care last month, % 16.7 13.5 25.6 30.0 31.3 19.7
Spent money on healthcare last month, % 17.3 13.8 24.9 29.8 29.4 19.8
Hospitalized last year, % 5.6 4.5 9.3 10.9 13.5 7.0
Descriptive characteristics
Enrolled in ART, % 0.0 0.0 42.6 47.2 49.4 14.3
Age, mean 34.3 32.0 36.2 38.5 39.2 34.9
Female, % 55.8 51.6 73.9 60.3 53.0 57.9
Married or cohabiting, % 68.4 53.6 67.7 67.8 69.0 65.3
No education, % 13.0 12.4 14.7 13.9 13.9 13.3
Some primary education, % 41.5 38.7 47.6 47.9 45.1 42.7
Completed primary, % 16.6 14.3 18.8 18.7 20.0 16.9
Some secondary, % 18.1 23.4 13.1 13.5 13.6 17.7
Completed secondary or higher, % 10.8 11.2 5.8 6.0 7.4 9.5
Wealth quintile, mean 3.2 3.4 3.0 2.9 3.0 3.2
Number of children, mean 3.5 3.5 3.0 2.9 2.9 3.3
Household size, mean 6.5 7.2 5.4 5.3 5.4 6.3
Abbreviations: No., Number; %, Percent; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy.
Notes: HIV-negative participants are stratified based on whether they resided with HIV-positive household member. Antiretroviral therapy status at baseline was
established using first medication pickup date. Participants were defined as being enrolled in ART if their first ART pickup date was before the CHC campaign began in
their community. Wealth, in quintiles, was calculated using Principal Components Analysis and is based on ownership of 47 items.
https://doi.org/10.1371/journal.pone.0198912.t001
High CD4 counts associated with better economic outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0198912 June 26, 2018 7 / 18
outcomes. Compared to the reference group of HIV-negative participants who did not reside
with an HIV-positive person, HIV-positive participants with CD4>500 had equal probability
of working in the past week as the reference group (marginal effect, ME 1.49; 95% confidence
interval, CI: -1.09, 4.08). HIV-positive participants with CD4 351–500, on the other hand,
were significantly less likely to have worked in the past week (ME -4.50; 95% CI -7.99, -1.01) as
were participants with CD4350 (ME -7.41; 95% CI -10.96, -3.85). Post-estimation Wald tests
showed HIV-positive participants with CD4>500 were more likely to have worked than par-
ticipants with CD4 351–500 and CD4350 (p<0.001 in both tests). We found largely similar
patterns when looking specifically at farm work, with HIV-positive participants with high
CD4 counts being similar to the reference group and those with low CD4 counts less likely to
be doing farm work. Being on ART was associated with higher probability of having done any
work in the past week (ME 3.34; 95% CI 0.59, 6.10) as well as any farm work (ME 4.65; 95% CI
1.60, 7.70).
Employment outcomes of HIV-negative adults. Among HIV-negative participants,
those residing in households with an HIV-positive person who had low CD4 counts (350 or
351–500) were less likely to be engaged in the labor force than the reference group (Table 3).
For example, those in households with an HIV-positive person with CD4350 were 6.28
Fig 1. Local polynomial graphs of employment and healthcare outcomes and CD4 counts among HIV-positive adults.
https://doi.org/10.1371/journal.pone.0198912.g001
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percentage points less likely to have worked in the past week (95% CI -10.75, -1.80) and 4.89
percentage points less likely to have done farm work in the past week (95% CI -9.74, -0.03). In
contrast, HIV-negative participants in household with an HIV-positive person with CD4>500
had statistically equal probability of working (ME -1.78; 95% CI -5.16, 1.59) as their counter-
parts in households with no HIV-positive persons. Post-estimation Wald tests showed that
probability of any work and farm work last week were statistically higher for individuals whose
household members had>500 CD4 counts than individuals whose household members had
CD4 351–500 (p = 0.029 and p = 0.019, respectively).
Health and healthcare utilization of HIV-positive adults. HIV-positive individuals in
all CD4 categories were significantly more likely to have experienced illness, lost time from
usual activities due to illness, sought healthcare, spent money on healthcare and to have been
hospitalized than HIV-negative participants in households with no HIV-negative persons
(Table 4). For example, compared to the reference group, probability of seeking healthcare in
the past month was much higher for HIV-positive participants with CD4>500 (ME 4.21; 95%
CI 1.75, 6.66), CD4 between 351–500 (ME 8.46; 95% CI 5.15, 11.76), and CD4350 (ME 9.63;
95% CI 6.31, 12.94). Participants with CD4350 were 6.75 percentage points more likely to
have been hospitalized in the past year than the reference group (95% CI 4.27, 9.22). In general,
HIV-positive participants with CD4350 and CD4 351–500 had similar healthcare utilization
levels and participants with CD4>500 had lower levels. However, the likelihood of hospitaliza-
tion in the past 12 months was significantly higher among those with CD4<350 than any
other study group.
Healthcare utilization of HIV-negative adults. HIV-negative participants who lived
with HIV-positive household members were less likely to lose time from usual activities due to
Table 2. Employment of HIV-positive working-age adults compared to HIV-negative adults living in households with no infected household members.
Any work
last week
Any farm work
last week
ME [95% CI] ME [95% CI]
HIV-, no HIV+ household member Ref Ref
HIV+, CD4 >500 1.49 [-1.09, 4.08] -2.20 [-5.12, 0.73]
HIV+, CD4 351–500 -4.50 [-7.99, -1.01] -3.78 [-7.50, -0.07]
HIV+, CD4 350 -7.41 [-10.96, -3.85] -9.52 [-13.22, -5.81]
Not on ART Ref Ref
On ART 3.34 [0.59, 6.10] 4.65 [1.60, 7.70]
Mean outcome for reference group 70.9 58.7
No. observations 9,182 9,182
P-values from post-estimation Wald tests
HIV+, CD4 >500 = HIV+, CD4 351–500 <0.001 0.402
HIV+, CD4 >500 = HIV+, CD4350 <0.001 <0.001
Abbreviations: ME, marginal effect; 95% CI, 95% confidence interval, HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy.Notes: GEE regression
models for working age adults (18–65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level. Marginal effects are
reported as percentage point changes. Reference group are HIV-negative participants who do not reside with HIV-positive household members. Models controlled for
education level, age, age-squared, gender, marital status, wealth index, number of children in household, number of household members and community indicators. P-
value notation
 p<0.001
 p<0.01
 p<0.05
https://doi.org/10.1371/journal.pone.0198912.t002
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own illness or care-seeking, and spend money on healthcare than their counterparts in house-
holds without an HIV-positive person (Table 5). For example, HIV-negative participants
whose household members had CD4 counts in the 351–500 range were 4.53 percentage points
less likely to lose time from activities due to illness in the past month (95% CI -7.82, -1.23),
3.31 percentage points less likely to seek or receive healthcare in the past month (95% CI -6.66,
0.03), and 3.85 percentage points less likely to spend money on healthcare (95% CI -7.25,
-0.45).
Associations based on ART status and viral load suppression. Finally, Fig 2 presents
findings from models where HIV-positive participants were sub-divided in CD4 groups based
on whether they had initiated ART and had achieved viral suppression. The subcategories are
presented in the order of how we conceptually assumed people transition through HIV disease
stages (i.e. declining CD4 counts for people not on ART or with detectable viral load and
improving CD4 counts for people on ART or with suppressed viral load). As can be seen from
the figures, declining CD4 counts were associated with progressively worse outcomes, with the
lowest probability of employment and highest probability of healthcare utilization and expen-
ditures found among those in with CD4<350. Higher CD4 counts among participants who
were on ART or who had achieved viral suppression was generally associated with better eco-
nomic outcomes. Notably, high CD4 participants not on ART who had detectable viral loads
(i.e. newly identified cases) were found to have similar probability of outcomes as the HIV-
negative participants. HIV-positive participants whose CD4 counts recovered to CD4>500
reported economic losses due to illness that were higher compared to both HIV-negative and
newly identified HIV-positive participants with high CD4.
Table 3. Employment of HIV-negative working-age adults who have HIV-positive household members compared to HIV-negative adults living in households with
no infected household members.
Any work
last week
Any farm work
last week
ME [95% CI] ME [95% CI]
HIV-, no HIV+ household member Ref. Ref.
HIV-, lives with HIV+ CD4 >500 -1.78 [-5.16, 1.59] -0.84 [-4.56, 2.88]
HIV-, lives with HIV+ CD4 351–500 -7.03 [-11.49, -2.57] -7.00 [-11.79, -2.21]
HIV-, lives with HIV+ CD4350 -6.28 [-10.76, -1.80] -4.89 [-9.74, -0.03]
No household member on ART Ref. Ref.
All HIV+ household members on ART 0.35 [-3.47, 4.17] 0.00 [-4.35, 4.36]
Some HIV+ household members on ART 2.60 [-5.97, 11.17] 1.76 [-8.56, 12.08]
Mean outcome for reference group 70.9 58.7
No. observations 7,874 7,874
P-values from post-estimation Wald tests
HIV-, CD4 >500 = HIV-, CD4 351–500 0.029 0.019
HIV-, CD4 >500 = HIV-, CD4350 0.056 0.117
Abbreviations: ME, marginal effect; 95% CI, 95% confidence interval, HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy.Notes: GEE regression
models for working age adults (18–65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level. Marginal effects are
reported as percentage point changes. Reference group are HIV-negative participants who do not reside with HIV-positive household members. Models controlled for
education level, age, age-squared, gender, marital status, wealth index, number of children in household, number of household members, and community indicators. P-
value notation
 p<0.001
 p<0.01
 p<0.05
https://doi.org/10.1371/journal.pone.0198912.t003
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Discussion
In this large, population-representative study from 32 communities participating in the
SEARCH trial in Kenya and Uganda, economic outcomes for HIV-positive adults with CD4
counts above 500 were significantly better than those for HIV-positive adults with CD4 counts
below 500, and also statistically equivalent to outcomes for HIV-negative adults. For HIV-neg-
ative household members of HIV-positive persons, higher CD4 count of an HIV-positive
household member was similarly protective of employment outcomes. Patterns in healthcare
utilization and healthcare costs incurred by HIV-positive individuals also indicated a benefit
to having higher CD4 counts, although the outcomes of those with CD4>500 remained worse
than those for HIV-negative persons in households not directly affected by HIV. Importantly,
even among HIV-positive participants who had not initiated ART or were not virally sup-
pressed, those with CD4>500 had better economic outcomes than those with lower CD4
counts, including in the mid-range of 351–500 cells/μL. These findings suggest that initiating
ART before CD4 counts decline substantially could generate economic benefits, though the
results need to be confirmed with longitudinal data to establish causality.
Prior population-based studies of adults initiating ART have often lacked data on key health
indicators such as the CD4 count and viral load of individuals, have relied on clinic-based sam-
ples that only included those who seek care, or have studied HIV-positive individuals in set-
tings where ART initiation typically did not occur until CD4 counts declined to threshold
levels such as 200, as specified in previous guidelines [10–17, 28]. Our study offers a more
Table 4. Illness and health seeking behaviors of HIV-positive working-age adults compared to HIV-negative adults living in households with no infected household
members.
Experienced illness
last month
Lost time from usual
activities due to illness
last month a
Sought or
received care
last month
Spent money on
healthcare
last month
Hospitalized
last year b
ME [95%CI] ME [95%CI] ME [95%CI] ME [95%CI] ME [95%CI]
HIV-, no HIV+ household member Ref. Ref. Ref. Ref. Ref.
HIV+, CD4 >500 3.22 [0.42, 6.03] 3.24 [0.81, 5.67] 4.21 [1.75, 6.66] 3.68 [1.21, 6.15] 2.04 [0.48, 3.60]
HIV+, CD4 351–500 8.72 [5.05, 12.39] 6.20 [2.98, 9.42] 8.46 [5.15, 11.76] 8.57 [5.23, 11.91] 3.95 [1.72, 6.17]
HIV+, CD4350 9.80 [6.15, 13.46] 7.42 [4.19, 10.66] 9.63 [6.31, 12.94] 7.93 [4.65, 11.22] 6.75 [4.27, 9.22]
Not on ART Ref. Ref. Ref. Ref. Ref.
On ART 1.68 [-1.27, 4.63] 1.58 [-0.97, 4.12] 2.99 [0.40, 5.59] 2.04 [-0.55, 4.62] 1.22 [-0.43, 2.86]
Mean outcome for reference group 28.2 17.1 16.7 17.3 5.6
No. observations 9,182 9,182 9,182 9,182 9,182
P-values for post-estimation Wald tests
HIV+, CD4 >500 = HIV+, CD4 351–500 0.003 0.072 0.011 0.004 0.094
HIV+, CD4 >500 = HIV+, CD4350 <0.001 0.011 0.001 0.011 <0.001
Abbreviations: ME, marginal effect; CI, confidence interval; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy
Notes: GEE regression models for working age adults (18–65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level.
Marginal effects are reported in percent changes. Reference group are HIV-negative participants who do not reside with HIV-positive household members. Models
controlled for education level, age, age-squared, gender, marital status, wealth index, number of children in household, number of household members, and community
indicators. P-value notation
 p<0.001
 p<0.01
 p<0.05
a Usual activities include paid and unpaid work such as household chores.
b Hospitalizations captured using one year recall period.
https://doi.org/10.1371/journal.pone.0198912.t004
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generalizable depiction of the association between CD4 counts and economic outcomes in the
general population. Although some previous studies have documented an individual-level
decline in employment outcomes in the years prior to ART initiation, followed by a rebound
in economic outcomes after initiating treatment at low CD4 counts [15, 29, 30], studies that
assess outcomes of large numbers of asymptomatic, high CD4 adults are lacking. Thus, our
study fills a gap in literature by including a large, population-representative sample that reflects
the communities that would benefit from “test and treat”. By and large, the findings from
our cross-sectional study are consistent with the hypothesis that population-level HIV testing
and early ART initiation may help avert an economic decline associated with HIV disease
progression.
Previous studies document that early ART initiation offers important individual health ben-
efits and reduces the risk of HIV transmission [1, 2]. Our study findings provide policymakers
with additional data on the potential economic gains of finding and treating persons with HIV
early in their disease course. It is particularly noteworthy that HIV-positive adults with
CD4>500 generally had significantly higher employment rates than even those with CD4 cell
counts between 351–500. It is important to recognize that our study precludes causal inference
and that further evidence from longitudinal assessments are needed to determine the causal
impact of early ART on economic outcomes. The associations we found do suggest, however,
that the benefits of early ART initiation may be sizable when it comes to outcomes such as
employment, healthcare utilization and expenditures.
Table 5. Illness and health seeking behaviors of HIV-negative working-age adults who have HIV-positive household members compared to HIV-negative adults liv-
ing in households with no infected household members.
Lost time from usual
activities due to illness last
month a
Sought or
received care
last month
Spent money on healthcare
last month
Hospitalized
last year b
ME [95%CI] ME [95%CI] ME [95%CI] ME [95%CI]
HIV-, no HIV+ household member Ref. Ref. Ref. Ref.
HIV-, lives with HIV+ CD4 >500 -1.74 [-4.58, 1.09] -0.85 [-3.68, 1.98] -1.18 [-4.08, 1.72] -0.14 [-1.85, 1.58]
HIV-, lives with HIV+ CD4 351–500 -4.53 [-7.82, -1.23] -3.31 [-6.66, 0.03] -3.85 [-7.25, -0.45] -0.36 [-2.54, 1.82]
HIV-, lives with HIV+ CD4350 -3.30 [-6.74, 0.13] -0.88 [-4.46, 2.71] -1.86 [-5.45, 1.74] -0.53 [-2.63, 1.57]
No household member on ART Ref. Ref. Ref. Ref.
All HIV+ household members on ART 3.15 [-0.70, 7.01] 1.74 [-1.89, 5.37] 2.42 [-1.36, 6.20] -0.29 [-2.30, 1.72]
Some HIV+ household members on ART -1.01 [-10.08, 8.07] -2.42 [-10.89, 6.05] -3.01 [-11.43, 5.40] -2.95 [-6.39, 0.48]
Mean outcome for reference group 17.1 16.7 17.3 5.6
No. observations 7,874 7,874 7,874 7,874
P-values for post-estimation Wald tests
HIV-, CD4 >500 = HIV-, CD4 351–500 0.129 0.191 0.161 0.856
HIV-, CD4 >500 = HIV-, CD4350 0.394 0.991 0.725 0.732
Abbreviations: ME, marginal effect; 95% CI, 95% confidence interval, HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy.
Notes: GEE regression models for working age adults (18–65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level.
Marginal effects are reported in as percentage point changes. Reference group are HIV-negative participants who do not reside with HIV-positive household members.
Models controlled for education level, age, age-squared, gender, marital status, wealth index, number of children in household, number of household members, and
community indicators. P-value notation
 p<0.001
 p<0.01
 p<0.05
a Usual activities include paid and unpaid work such as household chores.
b Hospitalizations captured using one year recall period.
https://doi.org/10.1371/journal.pone.0198912.t005
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This study is also noteworthy for its analysis of how HIV-negative household members are
affected by the health status on an HIV-positive person. The findings suggest several important
“spillover effects” of early HIV treatment. In households where HIV-positive adults had high
CD4 counts, HIV-negative household members typically had similar employment outcomes
as HIV-negative individuals in households without an HIV-positive person. This was not the
case in households where HIV-positive adults had CD4500. This finding suggests that main-
taining high CD4 counts can have population-level economic impacts that are greater than
those among HIV-positive persons alone. Consistent with this possibility, it is notable that a
recent study showed that the introduction of PEPFAR in SSA, which led to many HIV-positive
persons with low CD4 counts initiating ART, was associated with an increase in population-
level employment outcomes [17]. Another study found that proximity to ART increased work
hours of HIV-negative people whose households did not directly benefit from expanded treat-
ment [21]. Our study adds to the evidence indicating that ART may have spillover effects that
extend beyond the HIV-positive persons receiving treatment.
Fig 2. Association between CD4 count and socio-economic outcomes, based on ART status and viral load. Abbreviations: ART, antiretroviral
therapy; CI, confidence interval; DVL, detectable viral load, HIV+, HIV-positive; HIV-, HIV-negative; HH, household; ME, marginal effect. Notes:
Marginal effects, in percentage points, with 95% confidence intervals around them, were calculated after fitting GEE regression models for working age
adults (18–65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level. Reference group were HIV-
negative participants in households that did not have any HIV-positive adults. Models controlled for education level, age, age-squared, gender, marital
status, wealth index, number of children in household, number of household members, and community indicators.
https://doi.org/10.1371/journal.pone.0198912.g002
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Our findings also suggest that in households faced with high costs of care and treatment of
an HIV-positive person, other household members may be forgoing some of their routine
healthcare needs. This could have important future repercussions if untreated diseases of HIV-
negative individuals lead to worsening symptoms, costlier treatment, and exit from the labor
market. Thus, early access to ART may offer important cost savings at the population-level in
the long term. If these trends are confirmed in prospective analyses, future cost-effectiveness
studies should consider incorporating in their models the broader spillover effects of early
ART that we report here rather than relying solely on the individual costs and benefits for the
treated person [7].
Our findings have greater relevance given the recent focus on achieving 90-90-90 targets
through greatly expanded HIV testing and access to ART, the emphasis on the need for
increased resources to do this [6], as well as the accompanying concern that development assis-
tance for health has stagnated and future funding levels are uncertain [31]. The increased
demands on countries financing their own programs as well as the proposed cuts to U.S. for-
eign assistance [9] could undermine prospects of achieving the 90-90-90 targets in countries
that are most affected by HIV/AIDS. Along with a series of other economic studies, this analy-
sis provides compelling evidence of the economic and health system benefits that are associ-
ated with protecting and improving the health outcomes of HIV-positive persons. Evidence
presented in this study can be useful for governments of low-income countries for priority-set-
ting in their budgets and for US policy makers for decisions about future funding levels of for-
eign aid.
Key strengths of the paper include evaluating multiple socio-economic outcomes in large,
population-representative sample that included HIV-positive participants and their household
members. Access to laboratory-confirmed HIV status and CD4 counts allowed us to assess the
health status of study participants using objective measures. We measured important, yet sel-
dom evaluated, indirect costs associated with ART. Despite ART drugs being offered free of
charge to eligible patients in SSA, studies have documented significant costs associated with
being on ART, including drugs to treat opportunistic infections or comorbidities, non-routine
laboratory tests, medical consultations, and hospital stays [32–34]. We found that HIV-posi-
tive participants in all CD4 count categories reported more interactions with the healthcare
system, though high CD4 participants fared better than those with low CD4 counts. Some
results from this study also confirmed and extended previous findings about the associations
between severity of HIV disease, ART, and employment outcomes. Consistent with existing
literature, we found ART initiation was associated with better economic outcomes [10, 12, 19,
22, 28]. The findings for individuals with CD4 counts >500 confirmed, with greater precision,
the results from a small pilot study that our team conducted in one community in southwest-
ern Uganda [22].
Our study has several notable limitations. First, the study does not establish a causal rela-
tionship between the main health status measures (HIV status, CD4 count, and viral suppres-
sion status) and economic outcomes. In particular, the associations reported here may be
biased by uncontrolled confounding. One concern is selection bias stemming from the possi-
bility that HIV-positive individuals who sought treatment earlier may be more likely to benefit
from ART or have better underlying economic circumstances. Another concern is the possibil-
ity of reverse causality, with individuals who have better economic characteristics being more
likely to engage in care and achieve better health outcomes. Nonetheless, the overall consis-
tency of the main findings with other studies showing declining health in the years prior to
ART initiation suggests that such biases are not a major concern.
The study conclusions are further limited by the fact that HIV status was missing for more
than 2,500 (or 18%) of working-age adults who were part of the HSE survey and who were
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deemed to be stable residents at census. We compared descriptive characteristics and out-
comes of participants with missing HIV status and found that these participants were more
likely to be younger, single, male, and in school and were less likely to be working, experience
illness, lose time from work due to illness or use/pay for healthcare than our study participants.
Although participants with missing HIV status were more similar to HIV-negative participants
than HIV-positive participants in our sample, we can only speculate about their actual HIV
status and disease stage if HIV positive. If the participants with missing HIV status had lower
HIV prevalence than those not missing HIV status, then including them in our sample would
have magnified our study findings. If these participants had higher HIV prevalence and lower
CD4 counts than what was observed among those whose HIV status was measured, our find-
ings would also be underestimates. On the other hand, if the participants with missing HIV
status had a higher proportion of high CD4, HIV-positive adults, our findings would have
overestimated the association between high CD4 counts and economic outcomes. Follow-up
longitudinal data collection in the SEARCH trial is ongoing and we will be able to estimate the
causal effect of early ART initiation on various economic outcomes using prospective data
once the trial completes.
Another limitation is measurement bias. Many outcome measures were obtained in house-
hold surveys and could have suffered from recall bias. We attempted to limit these biases by
using short recall periods that are common in similar literature [35]. Moreover, the main indi-
cators of health status were laboratory-confirmed measures of HIV status and CD4 counts.
The use of objective measures of health status represents an advance in comparison to previous
studies that examined the link between health and economic outcomes, which relied on self-
reported health status [36]. ART status was based on treatment initiation dates rather than
adherence; this could have led to misclassification of some people as being on ART (and there-
fore having better health) even if they did not have high adherence. For this reason, it is possi-
ble that our estimates of the association between ART status and economic outcomes were
biased downward. Finally, the employment outcomes we relied on in this study were measures
of labor market participation rather than productivity. Future studies should incorporate more
robust measures of labor productivity to improve our understanding of how HIV impacts the
earning potential of people living with the disease.
Conclusion
At a time when countries most affected by the HIV epidemic face increasing financial chal-
lenges to fund the HIV response, our study provides evidence about the potential economic
benefits of earlier ART initiation. While we cannot draw causal conclusions, our findings pro-
vide important insights about the associations between the CD4 counts and ART use of HIV-
positive persons and the economic outcomes they and their HIV-negative household members
achieve. Future data from the SEARCH trial will enable us to test the hypothesis that early
ART initiation has a causal effect on individual- and household-level economic outcomes.
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